Skip to main content
. 2023 Oct 30;10(6):1741–1752. doi: 10.1007/s40744-023-00604-7

Table 1.

Participant characteristics

Treatment sequence
TCA + LOR LOR + TCA Total
N 20 20 40
Age (years)* 41.8 (6.9) 40.8 (7.7) 41.3 (7.2)
Race [n (%)]
 Black/African American 4 (20%) 4 (20%) 8 (20%)
 White 16 (80%) 16 (80%) 32 (80%)
Sex [n (%)]
 Female 9 (45%) 7 (35%) 16 (40%)
 Male 11 (55%) 13 (65%) 24 (60%)
Body mass index (kg/m2)* 27.36 (2.99) 28.25 (2.97) 27.80 (2.98)

*Mean (SD) presented

TCA triamcinolone acetonide, LOR lorecivivint